Evofem Biosciences, Inc. (EVFM)
OTCMKTS
· Delayed Price · Currency is USD
0.0088
0.00 (0.00%)
Apr 1, 2025, 3:12 PM EST
Evofem Biosciences Revenue
In the year 2024, Evofem Biosciences had annual revenue of $19.36M with 6.28% growth. Evofem Biosciences had revenue of $7.10M in the quarter ending December 31, 2024, with 46.81% growth.
Revenue
19.36M
Revenue Growth
+6.28%
P/S Ratio
0.04
Revenue / Employee
605.09K
Employees
32
Market Cap
1.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.36M | 1.15M | 6.28% |
| Dec 31, 2023 | 18.22M | 1.38M | 8.20% |
| Dec 31, 2022 | 16.84M | 8.59M | 104.23% |
| Dec 31, 2021 | 8.24M | 7.80M | 1,748.43% |
| Dec 31, 2020 | 446.00K | - | - |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| SS Innovations International | 16.04M |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| American Oncology Network | 1.76B |
Evofem Biosciences News
- 6 days ago - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - PRNewsWire
- 8 days ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire
- 12 days ago - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product - GlobeNewsWire
- 6 weeks ago - Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO - PRNewsWire
- 4 months ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - PRNewsWire
- 5 months ago - Evofem Secures Investor Support for Proposed Merger through Voting Agreements - PRNewsWire
- 8 months ago - Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution - PRNewsWire
- 8 months ago - Evofem Biosciences GAAP EPS of $0.00, revenue of $4.16M - Seeking Alpha